PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23461841-7 2013 Since FFAs are known to be involved in the development of insulin resistance, these results suggest that spironolactone may be useful for lowering insulin resistance in PCOS patients. Spironolactone 105-119 insulin Homo sapiens 58-65 8845091-10 1995 Thiazide diuretics, spironolactone, and beta-adrenergic blockers impair insulin sensitivity. Spironolactone 20-34 insulin Homo sapiens 72-79 24405838-11 2014 CONCLUSIONS: Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs. Spironolactone 13-27 insulin Homo sapiens 54-61 35345424-0 2022 Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study. Spironolactone 20-34 insulin Homo sapiens 83-90 35345424-2 2022 To compare the effects and safety of low-dose spironolactone combined with metformin or either drug alone on insulin resistance (IR) and functional improvement in patients with PCOS, this was a single-center, randomized, open-label, pilot study of patients with PCOS at the Third Affiliated Hospital of Guangzhou Medical University between 01/2014 and 01/2016. Spironolactone 46-60 insulin Homo sapiens 109-116 33261310-9 2020 Treatment with spironolactone was the only risk factor associated with PAC >30 ng/dL (odds ratio, 5.2; 95% confidence interval [CI], 2.7 to 10; P<0.001) and conferred a 2.48-fold risk of insulin resistance after 1 year compared with surgery (95% CI, 1.3 to 4.8; P=0.007). Spironolactone 15-29 insulin Homo sapiens 187-194 33261310-10 2020 Conclusion: Spironolactone treatment might increase insulin resistance in patients with PA. Spironolactone 12-26 insulin Homo sapiens 52-59 25337775-0 2015 Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Spironolactone 63-77 insulin Homo sapiens 0-7 25337775-3 2015 Treatment with the mineralocorticoid receptor blocker spironolactone ameliorated insulin resistance in patients, and impaired glucose tolerance was partially reversed in fifth/sixth nephrectomized rats. Spironolactone 54-68 insulin Homo sapiens 81-88 24405838-0 2014 Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. Spironolactone 0-14 insulin Homo sapiens 41-48 24405838-3 2014 This study aimed to evaluate the effects of the aldosterone blocker spironolactone, in comparison with furosemide, on insulin resistance in CHF patients. Spironolactone 68-82 insulin Homo sapiens 118-125 24405838-6 2014 Fasting plasma glucose was not changed; however, plasma insulin levels decreased and insulin sensitivity (by homeostasis model assessment: HOMA-IR) improved with spironolactone as compared to furosemide (p<0.0005). Spironolactone 162-176 insulin Homo sapiens 85-92 23461841-7 2013 Since FFAs are known to be involved in the development of insulin resistance, these results suggest that spironolactone may be useful for lowering insulin resistance in PCOS patients. Spironolactone 105-119 insulin Homo sapiens 147-154 18075971-5 2007 Spironolactone, but not its active metabolite canrenoic acid, significantly increased basal and insulin-stimulated glucose uptake in cultured IN VITRO-differentiated adipocytes of women, without affecting insulin sensitivity. Spironolactone 0-14 insulin Homo sapiens 96-103 22733474-0 2012 Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Spironolactone 0-14 insulin Homo sapiens 74-81 22733474-7 2012 In conclusion, our study demonstrates beneficial effects of spironolactone in attenuating both chlorthalidone-induced sympathetic activation and insulin resistance in humans, independent of blood pressure reduction. Spironolactone 60-74 insulin Homo sapiens 145-152 21436212-0 2011 Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. Spironolactone 10-24 insulin Homo sapiens 73-80 21436212-9 2011 CONCLUSIONS: Spironolactone and vitamin E combined therapy seems to exhibit a favourable effect on serum insulin and HOMA-IR in patients with NAFLD. Spironolactone 13-27 insulin Homo sapiens 105-112 17885557-12 2007 After the spironolactone treatment, we found an increase of C-peptide and insulin levels without changes in HOMA-IR or HOMA-betaF. Spironolactone 10-24 insulin Homo sapiens 74-81 15816371-0 2005 Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. Spironolactone 0-14 insulin Homo sapiens 92-99 15816371-5 2005 The insulin levels at 60 min during OGTT, homeostasis model assessment-insulin resistance and area under curve of insulin were significantly lowered in overweight women after 12 months of spironolactone and weight loss and no negative changes in insulin secretion and sensitivity were observed in PCOS women after pharmacological treatment alone. Spironolactone 188-202 insulin Homo sapiens 4-11 15816371-5 2005 The insulin levels at 60 min during OGTT, homeostasis model assessment-insulin resistance and area under curve of insulin were significantly lowered in overweight women after 12 months of spironolactone and weight loss and no negative changes in insulin secretion and sensitivity were observed in PCOS women after pharmacological treatment alone. Spironolactone 188-202 insulin Homo sapiens 71-78 15816371-5 2005 The insulin levels at 60 min during OGTT, homeostasis model assessment-insulin resistance and area under curve of insulin were significantly lowered in overweight women after 12 months of spironolactone and weight loss and no negative changes in insulin secretion and sensitivity were observed in PCOS women after pharmacological treatment alone. Spironolactone 188-202 insulin Homo sapiens 71-78